search
Back to results

Effect of Creatine on Serum and Urine Creatinine (ECSUC)

Primary Purpose

Acute Kidney Injury

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Creatine Monohydrate
Creatine Ethyl Ester
Sponsored by
Beth Israel Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Acute Kidney Injury focused on measuring Creatine, Creatinine, Serum Creatinine, Urine Creatinine, Creatine Monohydrate, Creatine Ethyl Ester, Acute Kidney Injury, Renal, Kidney

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age over 18
  • Human

Exclusion Criteria:

  • Use of any form of creatine within 4 weeks prior to participation in study.
  • Pregnancy
  • History of elevated creatinine or renal insufficiency
  • History of PKU

Sites / Locations

  • Beth Israel Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Creatine Monohydrate

Creatine Ethyl Ester

Arm Description

Each of the 25 subjects took Creatine Monohydrate.

Each of the 25 subjects took Creatine Ethyl Ester.

Outcomes

Primary Outcome Measures

Serum Creatinine
Participants ingested 10 grams of creatine monohydrate or creatine ester and had serum creatinine measured at 0, 1, 2, 3, 4, 5, and 24 hours.
Urine Creatinine
Participants ingested 10 grams of creatine monohydrate or creatine ethyl ester and had urinary creatinine levels measured at 0, 1.5, 3, 5, and 24 hours.

Secondary Outcome Measures

Full Information

First Posted
June 6, 2011
Last Updated
September 14, 2012
Sponsor
Beth Israel Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01367717
Brief Title
Effect of Creatine on Serum and Urine Creatinine
Acronym
ECSUC
Official Title
Effect of Creatine Monohydrate and Creatine Ethyl Ester on Serum and Urinary Creatinine
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
June 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beth Israel Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background: Creatinine (Crn) concentration is used to assess renal function via calculation of GFR (Glomerular Filtration Rate). By RIFLE (Risk, Injury, Failure, Loss, End Stage Kidney Disease) criteria, acute kidney injury (AKI) and acute renal failure (ARF) are defined by a two-fold and three-fold increase in serum Crn, respectively. Crn is a breakdown product of proteins and circulating creatine, and it is generally a benign product present in serum. Creatine is a nutritional supplement that has been available since 1993, and it is widely used among athletes today. Methods: In an IRB approved, blinded crossover trial, 25 human volunteers ingested 2 creatine supplements to determine any associated statistically significant increase in serum Crn and clinically significant increase in serum Crn to a degree associated with AKI or ARF. Urine samples were also collected to examine excretion patterns after an ingested sample. Participants ingested 10 gm of creatine ethyl ester (CEE) or creatine monohydrate (CrM) and had serum Crn assayed at 0, 1, 2, 3, 4, 5 and 24 hours. Urinary Crn levels were assayed at 0, 1.5, 3, 5 and 24 hours. Exclusion factors were any history of renal disease or use of creatine within the last month. Statistical analysis was performed by Wilcoxon Matched-Pair Signed Ranks Test and descriptive summary statistics were performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury
Keywords
Creatine, Creatinine, Serum Creatinine, Urine Creatinine, Creatine Monohydrate, Creatine Ethyl Ester, Acute Kidney Injury, Renal, Kidney

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Creatine Monohydrate
Arm Type
Active Comparator
Arm Description
Each of the 25 subjects took Creatine Monohydrate.
Arm Title
Creatine Ethyl Ester
Arm Type
Active Comparator
Arm Description
Each of the 25 subjects took Creatine Ethyl Ester.
Intervention Type
Dietary Supplement
Intervention Name(s)
Creatine Monohydrate
Other Intervention Name(s)
GNC Pro Performance Fruit Punch Creatine Monohydrate, Tang brand Orange Drink, manufactured by Kraft Foods
Intervention Description
Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
Intervention Type
Dietary Supplement
Intervention Name(s)
Creatine Ethyl Ester
Other Intervention Name(s)
CE2 Rapid Absorption Ester Creatine: Platinum, Tang brand Orange Drink, manufactured by Kraft Foods
Intervention Description
Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
Primary Outcome Measure Information:
Title
Serum Creatinine
Description
Participants ingested 10 grams of creatine monohydrate or creatine ester and had serum creatinine measured at 0, 1, 2, 3, 4, 5, and 24 hours.
Time Frame
24 Hours
Title
Urine Creatinine
Description
Participants ingested 10 grams of creatine monohydrate or creatine ethyl ester and had urinary creatinine levels measured at 0, 1.5, 3, 5, and 24 hours.
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age over 18 Human Exclusion Criteria: Use of any form of creatine within 4 weeks prior to participation in study. Pregnancy History of elevated creatinine or renal insufficiency History of PKU
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristopher K Hunt, M.D.
Organizational Affiliation
Beth Israel Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert J Hoffman, M.D.
Organizational Affiliation
Beth Israel Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
Beth Israel Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effect of Creatine on Serum and Urine Creatinine

We'll reach out to this number within 24 hrs